18 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in EASI From Baseline to Week 16Primary· Week 0 to Week 16
The Eczema Area and Severity Index (EASI) is a validated measure used in clinical trials to evaluate the extent and severity of atopic dermatitis. EASI is a composite score ranging from 0 to 72 with higher scores indicating a more extensive or severe condition.
Group
Value
95% CI
LEO 152020 - Dosing Regimen 1 (Higher Dose)
-9.99
-12.85 – -7.13
LEO 152020 - Dosing Regimen 2 (Middle Dose)
-8.83
-12.63 – -5.04
LEO 152020 - Dosing Regimen 3 (Lower Dose)
-8.87
-12.47 – -5.28
LEO 152020 - Placebo
-9.11
-11.88 – -6.35
Number of Adverse Events From Baseline to Week 16+3 Days Per SubjectSecondary· Week 0 to Week 16+3 days
Only treatment-emergent adverse events will be reported for this outcome measure. An adverse event will be considered treatment emergent if occurring after the first dose of treatment (Week 0) and up until 3 days after the last dose of treatment (Week 16+3 days for a participant completing the 16-week treatment period).
Group
Value
95% CI
LEO 152020 - Dosing Regimen 1 (Higher Dose)
109
LEO 152020 - Dosing Regimen 2 (Middle Dose)
67
LEO 152020 - Dosing Regimen 3 (Lower Dose)
80
LEO 152020 - Placebo
75
Adverse events — posted to ClinicalTrials.gov
Time frame: Week 0 to Week 16+3 days.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
LEO 152020 - Dosing Regimen 1 (Higher Dose)
Serious: 0/61 (0%)
Deaths: 0/61
LEO 152020 - Dosing Regimen 2 (Middle Dose)
Serious: 2/45 (4%)
Deaths: 0/45
LEO 152020 - Dosing Regimen 3 (Lower Dose)
Serious: 1/49 (2%)
Deaths: 0/49
LEO 152020 - Placebo
Serious: 0/61 (0%)
Deaths: 0/61
Serious adverse events (2 terms)
Reaction
System
LEO 152020 - Dosing Regime…
LEO 152020 - Dosing Regime…
LEO 152020 - Dosing Regime…
LEO 152020 - Placebo
Eczema herpeticum
Infections and infestations
—
—
—
—
Malignant melanoma in situ
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD).
The purpose of the study is to test a new tablet (LEO 152020) to see if it improves AD and what the side effects are when compared with a placebo tablet with no medical ingredient.
During the study, there will be a 16-week treatment period during which the participants will be asked to take the tablets. The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD. The participants will also be asked to answer questions about their AD symptoms, itch, sleep, and quality of life.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi
· Phase 1
· recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis
· Phase 2
· recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
· Phase 1
· recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit
· recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E
· Phase 1
· recruiting
Other JW Pharmaceutical trials
Trials by the same sponsor.
NCT07514780 — To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers
· Phase 1
· not yet recruiting
NCT07378098 — to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
· Phase 3
· recruiting
NCT07374406 — To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers
· Phase 1
· recruiting
NCT07442006 — Glycemic Variability of Combination Therapies in T2DM
· Phase 4
· recruiting
NCT07036458 — To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects
· Phase 1
· active not recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by JW Pharmaceutical
Last refreshed: 4 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05117060.